This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tenet Q3 Earnings Beat on Strong Ambulatory Unit, '24 EPS View Raised
by Zacks Equity Research
THC's Q3 results benefit from higher same-hospital admissions and Medicaid supplemental revenue gains. Cost-cutting measures help offset challenges from hospital divestitures.
Should You Buy, Hold or Sell HCA Healthcare Stock After Q3 Earnings?
by Zubia Masood
HCA is poised to benefit from volume growth and expansion initiatives.
HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View
by Zacks Equity Research
HCA's quarterly results benefit from improved admissions and inpatient surgeries, partially offset by the impact of hurricanes and rising salaries and benefits expenses.
A Dose of Growth? Why Tenet Healthcare Could be a Buy Pre-Q3 Earnings
by Kaibalya Pravo Dey
THC's third-quarter results are likely to reflect growing patient admissions, utilization and patient days.
HCA (HCA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HCA Healthcare (HCA) Beats Q3 Earnings Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 1.61% and 0.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Universal Health Services (UHS) Lags Q3 Earnings Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of -1.07% and 1.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HCA Healthcare Pre-Q3 Earnings: Healthy Buy or a Diagnosis to Wait?
by Zubia Masood
HCA's third-quarter earnings are likely to benefit from improved admissions, capacity additions and payer mix, partially offset by rising operating expenses.
Tenet Healthcare (THC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Tenet (THC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insights Into HCA (HCA) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of HCA (HCA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Analyzing Universal Health Pre-Q3 Earnings: Time to Buy the Stock?
by Debasmita Chatterjee
UHS' Q3 results are likely to be driven by rising admissions in acute care hospitals and higher revenue per adjusted patient day in behavioral health hospitals.
Bargain or Bust? Decoding Tenet Healthcare Stock's Lower Valuation
by Kaibalya Pravo Dey
THC is well-positioned to benefit from the growing demand for hospital services. Yet, rising costs can potentially squeeze its margin growth.
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Healthcare Ventures in South Carolina With Three Buyouts
by Zacks Equity Research
ACHC expands its CTC network by acquiring three opioid treatment program clinics in South Carolina.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Brookdale Q3 2024 Occupancy Jumps, Logs 35th Straight Monthly Boost
by Zacks Equity Research
BKD's weighted average occupancy for September grows 30 bps sequentially.
Community Health Teams Up With Denim to Scale Conversational AI
by Zacks Equity Research
With this move, CYH intends to streamline agent workload, which can result in more savings for the company.
Here's Why You Should Add Elevance Health Stock to Your Portfolio
by Zacks Equity Research
ELV benefits from an increase in employer group fee-based memberships, partially offsetting the impact of Medicaid memberships.
Does Universal Health's Low P/E Ratio Signal a Suitable Entry Point?
by Debasmita Chatterjee
UHS rides on increased patient volumes. It can effectively cater to its patients through its extensive treatment network.
Sector ETFs & Stocks to Gain On Upbeat September Jobs Data
by Sanghamitra Saha
Nonfarm payrolls increased by 254, 000 jobs in September, the most since March.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Compelling Reasons to Hold on to Encompass Health Stock Right Now
by Zacks Equity Research
EHC remains well-poised for growth on the back of improved revenues, an extensive rehabilitation hospital network and sufficient cash-generating abilities.